After Second Stumble With Viramidine Pivotal Trial, Valeant Falls Back to Phase II
This article was originally published in The Pink Sheet Daily
Executive Summary
Company will reconsider dosing for its hepatitis C candidate.
You may also be interested in...
Valeant CEO Timothy Tyson and President, North America Wesley Wheeler: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Valeant execs outline development plans for taribavirin for hepatitis C, licensing opportunities and goals for ramping up the commercial organization ahead of potential new launches.
Valeant CEO Timothy Tyson and President, North America Wesley Wheeler: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Valeant execs outline development plans for taribavirin for hepatitis C, licensing opportunities and goals for ramping up the commercial organization ahead of potential new launches.
Valeant Weighs New Viramidine Dosing After Phase III Stumble
Prediction of a 2007 launch is unaltered by failure of first pivotal hepatitis C trial to meet one of two co-primary endpoints.